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Richard J. Gralla, MD,y and Frank Griesinger, MD, PhDAbstract: The design and analysis of clinical trials are crucial if
we are confidently to answer important questions regarding the
treatment of patients with non-small cell lung cancer. Survival,
response, and quality of life (QoL) are considered the key endpoints
of oncology clinical trials. Survival is the primary endpoint of most
randomized, phase III clinical trials, but small improvements in
survival are difficult to detect without a sufficiently large sample
size. Meta-analysis is a useful technique to increase statistical
precision and better estimate the magnitude of a treatment effect.
Although survival data guide treatment choice, the objective
response is generally the parameter used to evaluate treatment in
the clinic, despite its inherent unreliability. The objective response
rate remains an important outcome for early phase clinical trials.
QoL, which is a particularly important trial endpoint if survival
differences are unlikely may, however, be a more relevant outcome
in the clinic. Several validated QoL tools are available for use both
in trials and in daily practice, but many clinicians do not routinely
assess QoL when evaluating an individual patient’s response
to treatment. Recent advances in electronic technology make
capturing QoL data at each office visit not only possible but
practical, reliable, and useful for both patients and clinicians.
Therefore, although survival, response, and QoL can all be relevant
clinical trial endpoints, QoL may be the most relevant endpoint to
assess in the clinic.
Key Words: Non-small cell lung cancer, Endpoints, Quality
of life, Response, Survival, Docetaxel.
(J Thorac Oncol. 2007; suppl. 2: S51–S58)INTRODUCTION
Providing the best treatment for patients with lung cancerrequires a clear interpretation of the results of clinical
trials. Trials differ, however, in the population studied, the
analytical methods used, and the treatments evaluated.
Health services research groups in oncology have identified
survival, response, and quality of life (QoL) as the key
endpoints in clinical trials. In large randomized trials,
response is generally not considered to be sufficiently
reliable to be a primary endpoint, but may be useful in small
studies estimating some degree of anticancer activity. Other Adis Data Information BV. Una
lliance, New York, New York, USA, and the
en, Department of Hematology and Oncol-
ny
Richard J. Gralla, MD, New York Lung Cancer
Avenue, New York, NY 10024, USA
x: +1 801 365 6442; e-mail: rgralla@att.net
ternational Association for the Study of Lung
0S51
ology * Volume 2, Number 6, Supplemenendpoints, such as disease-free survival, duration of
response, and symptom control, are related to these key
areas, but are seen as secondary endpoints in patients with
lung cancer. The role of each of these endpoints differs
between clinical trial interpretation and clinical decision-
making for individual patients. Survival results are clearly
important when recommending a particular treatment, but are
not helpful once the patient is receiving therapy. Response is
generally the endpoint used in clinical decision-making, but it
is the least reliable, most expensive, and most intrusive
endpoint to assess. It may be of little value to patients unless
accompanied by an improvement in survival, QoL, or both.
QoL is an increasingly reliable endpoint that is feasible to
evaluate in the clinic. This review examines the strengths,
weaknesses, and appropriate use of each of the key endpoints.
SURVIVAL
Overall survival is widely accepted as the most
appropriate endpoint for randomized clinical trials. It is
reliable, realistic, objective, and easily determined. A
treatment that produces a significant survival benefit in a
well-designed randomized trial is likely to garner regulatory
approval in the United States and Europe. The US Food and
Drug Administration and the European Medicines Agency
consider overall survival the most appropriate endpoint for
non-small cell lung cancer (NSCLC) clinical trials. When
considering survival, however, we must distinguish larger
treatment goals from reasonable trial endpoints. For
example, increasing median survival from 8 to 12 months
may be a laudable long-term goal in advanced NSCLC, but it
is not an appropriate endpoint for a clinical trial. Realistic
differences between treatment arms are likely to be small,
and to detect small differences, a relatively large sample size
is required. Statistical power can be increased by pooling the
results of randomized clinical trials with meta-analytical
techniques. Meta-analysis can also be used to increase the
precision of the treatment effect and to reconcile seemingly
discordant clinical trial results. In NSCLC, meta-analyses
have confirmed the benefit of chemotherapy over best
supportive care, supported the use of chemotherapy in the
adjuvant setting, established the superiority of doublets
over monotherapy but the lack of additional benefit with
three-drug regimens, and indicated response and survival
advantages with cisplatin compared with carboplatin or
other non-platinum-based regimens (Table 1).1–7
Despite the improvements in survival associated with
cisplatin-based therapy, many clinicians have remaineduthorized reproduction of this article is prohibited.
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TABLE 1. Results of Meta-Analyses in Non-small Cell Lung Cancer.
Study Studies Included Combined N Comparison Outcome
Advanced disease
NSCLC Collaborative
Group1 (1995)
8 RCT 778 Combination, cisplatin-based
chemo vs BSC
27% reduction in risk of death
when chemotherapy added to
BSC (HR 0.73, p< 0.0001)
Equivalent to increase in MST
of 1.5 months
Delbaldo et al.2 65 RCT 13 601 (1) Doublet vs single-agent
therapy
20% reduction in odds of death
at 1 year with doublet therapy
(OR 0.80, p< 0.001)
(2) Triplet vs doublet therapy No difference (OR 1.01)
for triplet vs doublet
Hotta et al.3 8 RCT 2948 Cisplatin-based vs carboplatin-
based chemo
No survival advantage with cisplatin
overall (HR 1.05, p¼ 0.5)
Cisplatin plus new agent improved
MST relative to carboplatin plus
new agent (HR 1.106, p¼ 0.039)
Barlesi et al.4 14 RCT 5943 Cisplatin-based vs non-
platinum combination
chemo
12% reduction in risk of death
at 1 year with cisplatin-based
therapy (OR 0.88, p¼ 0.04)
Adjuvant therapy
Bria et al.5 11 RCT, 1 meta-
analysis
6494 Platinum-based chemo vs no
chemo after surgery
7% reduction in risk of death with
chemotherapy (HR 0.93, p¼ 0.01)
3.1% increase in survival
(absolute benefit)
BSC, best supportive care; chemo, chemotherapy; HR, hazard ratio; MST, median survival time; OR, odds ratio; RCT, randomized clinical trial.
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Numerous trials have been conducted in an effort to find
alternatives to cisplatin-based therapy that retain its efficacy
but reduce toxicity. Again, because no one trial has provided
a definitive answer, four groups have conducted meta-
analyses to evaluate the specific contribution of cisplatin to
the efficacy of combination chemotherapy for NSCLC.3,4,6,7
In the Japanese study, data from 2948 patients enrolled in
eight randomized trials that compared cisplatin-based with
carboplatin-based combination chemotherapy were used.3
Three trials combined the platinum agent with etoposide,
mitomycin, vindesine, or vinblastine, all older agents that
are no longer recommended in clinical practice guidelines.
The remaining five trials utilized new agents: docetaxel,
paclitaxel, or gemcitabine. When all trials were included,
cisplatin-based therapy was associated with a 5% gain in
overall survival ( p¼ 0.5); however, when just the results
from the trials that utilized new agents were included, the
survival benefit with cisplatin doubled (11%; hazard ratio
[HR] 1.106, p¼ 0.039). Grade 3/4 nausea and vomiting were
significantly more common with cisplatin, whereas grade
3/4 thrombocytopenia was significantly more common with
carboplatin. The number of treatment-related deaths was
small in both cohorts (3.9 and 2.9%, respectively). The
higher risk of treatment-related death with cisplatin-based
therapy was not statistically significant (odds ratio [OR]
1.36, 95% confidence interval [CI] 0.89–2.07). Similar
results were reported in a comprehensive review of
randomized studies in over 2300 patients.6Copyright © Adis Data Information BV. Una
S52In a similar analysis, cisplatin-based therapy was
associated with a 12% reduction in the relative risk of
death when compared with non-platinum combination
chemotherapy.5 This meta-analysis included results from
14 randomized trials with 5943 patients. Most trials
evaluated doublets and most used one of the newer agents.
Statistical heterogeneity related to the inclusion of trials that
utilized triplets was detected, and when these trials were
excluded, cisplatin-based chemotherapy was associated
with a significant reduction in the odds of death at 1 year
(OR 0.88, p¼ 0.04). Although toxicity was generally greater
with cisplatin-based therapy, there was no difference in the
rate of treatment-related mortality. Studies comparing
cisplatin-containing regimens with carboplatin regimens,
such as the Southwest Oncology Group 9509 trial,8 found no
difference in patient-expressed QoL using the validated
FACT-L instrument. All of the above studies were ‘literature
based’ meta-analyses. The first individual patient data-based
meta-analysis was recently presented, which investigated
this question.7 This study produced very similar results,
showing a highly significant improvement in the response
rate in patients randomly assigned to cisplatin regimens
compared with carboplatin. As in the Hotta meta-analysis,
survival was modestly improved in the cisplatin group, with
significant differences seen in those patients receiving third-
generation two-agent regimens. Of additional interest is the
finding of the similar results determined from both the
literature-based and the individual patient data meta-
analyses methods.uthorized reproduction of this article is prohibited.
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meta-analysis is the optimal number of agents in the
chemotherapy regimen when treating advanced NSCLC.
Using data from 65 trials that enrolled 13 601 patients,
Delbaldo and colleagues2 compared outcomes for single-
agent regimens and doublets and for doublet and triplet
regimens. Adding a second drug to single-agent therapy
significantly improved 1-year survival rates (OR 0.80,
p< 0.001) from approximately 30 to 35%; the median
survival was extended 17% ( p< 0.001). Conversely, adding
a third drug to a doublet regimen did not improve survival at
1 year (OR 1.01, p¼ 0.88) or impact median survival time,
which suggests that triplet regimens should not be routinely
prescribed outside of clinical trials.
Finally, a recent meta-analysis further illuminated the
role of adjuvant chemotherapy in the management of
NSCLC.5 The 1995 meta-analysis suggested a survival
benefit with cisplatin-based adjuvant therapy, and a number of
additional trials, some with conflicting results, have been
conducted since that time. In the current analysis, a total of 11
randomized trials and one meta-analysis that evaluated
platinum-based adjuvant chemotherapy in a total of
6494 patients with NSCLC was included. Adjuvant chemo-
therapy improved survival overall (HR 0.93, p¼ 0.01), and
the results were consistent in all predefined subgroups, such as
stage I/II patients (HR 0.87, p¼ 0.002) compared with stage
III patients (HR 0.93, p¼ 0.07). The absolute benefit was a
3.1% increase in overall survival when all data were included,
and a 3.9% increase using recent trial data, but not the data
included in the 1995 meta-analysis. Although the magnitude
of the survival benefit is small, the potential gain in life-years
is large, given the prevalence of NSCLC.
Enhancing the results from the Bria meta-analysis, a
recently presented individual patient-based meta-analysis
examined the question of the benefit of adjuvant
chemotherapy in NSCLC.9 The study differed somewhat
from the Bria meta-analysis, in that it only included trials
reported since 2000. Nonetheless, its overall result was
similar, showing a significant benefit for the use of cisplatin-
based chemotherapy. Several subset analyses were
presented, including a dose-related benefit with cisplatin,
and a lesser benefit in patients presenting with stage
I disease. The final manuscript, which may also examine
questions such as benefit by age group, is eagerly awaited.
Overall, meta-analyses have been used in NSCLC to
resolve major issues regarding when and how to treat patients.
The intervention with the greatest impact on survival is simply
to treat patients, which reduces the relative risk of death by
25–50%.1–7,9 Other strategies produce more modest, yet still
significant, survival gains. Therefore, when comparing two
active treatments and seeking to demonstrate an incremental
survival gain in an NSCLC clinical trial, sample size
considerations and realistic treatment goals are crucial if a
small survival difference is to be detected.
RESPONSE RATE
The objective response rate is an important endpoint for
uncontrolled phase II trials, in which it is used to estimate theCopyright © Adis Data Information BV. Una
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clinical trials, response is commonly used to monitor
treatment. It is, however, considered an unreliable endpoint
because it is depends on the accuracy of serial tumor
measurements. With traditional X-ray or computed tom-
ography (CT) techniques, the technical quality and repro-
ducibility of the images, along with intra- and interobserver
variability, impact the accuracy of tumor measurements.
When misclassifications result, patients may be removed
erroneously from effective therapy. Accurate response
classification is critical if response is used to guide therapy.
In a study designed to assess intra- and interobserver
variability in evaluating lung tumor size on CT scan,
Erasmus and colleagues10 reported that measurements on
CT scans are often inconsistent, even when performed by the
same thoracic radiologist, and these discrepancies result in
misclassifications for response. Interobserver variability was
greater than intraobserver variability in that study.
Progressive disease was mistakenly assigned to 30 and
43% of unidimensional and bidimensional lesions, respect-
ively, when measured by different observers, and to 9 and
22%, respectively, when measured a second time by the
same observer. On the basis of these results, it seems prudent
that for any given patient participating in a clinical trial,
serial tumor measurements and response classifications
should be performed by the same clinician for the duration
of the trial.
Clinical trials with induction chemotherapy for resect-
able NSCLC offer an opportunity to evaluate whether
response correlates with other outcomes of interest. Serial
measurements can be performed after the investigational
therapy but before surgery. Pathological complete response
(pCR) correlates with improved survival in this setting, but
clinical CT scan-based assessments of response have been
shown to underestimate the pCR rate.11 The French Thoracic
Cooperative Group demonstrated that both investigators and
members of an external review committee failed to classify
patients with a pCR as having had a clinical complete
response on CT. Among the 19 patients with a pCR,
investigators correctly classified six as having a complete
response, whereas the review committee only identified three
of these patients. Although investigators’ results had higher
sensitivity and specificity than the review committee, neither
group was sufficiently reliable if treatment decisions were to
be made on the basis of clinical response.
Positron emission tomography (PET) has the potential to
improve the accuracy of response assessment in NSCLC and
provide additional prognostic information. PET imaging
relies on functional properties of the tumor rather than its
structural or anatomical properties. NSCLC cells are par-
ticularly sensitive to 18F-fluorodeoxyglucose, a glucose
analog that is rapidly taken up by cells with increased
glucose metabolism. As such, serial 18F-fluorodeoxyglucose
PET measurements can be used to evaluate changes in
tumor volume and response to therapy. In a study involving
73 patients with NSCLC undergoing radiotherapy or
chemoradiotherapy,12 PET response was a more powerful
prognostic factor than CT response, disease stage, or baselineuthorized reproduction of this article is prohibited.
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response individually correlated with survival, only PET
response was significant in multivariate analysis.
Others have shown that PET response is prognostic for
patients undergoing induction chemotherapy.13,14 In one
study, PET response in the mediastinal lymph nodes predicted
survival, but CT response did not (PET HR 2.33, p¼ 0.04; CT
HR 1.87, p¼ 0.14). In addition, among patients with a
response on CT, the results of the PET scan further stratified
patients with different survival probabilities. PET may also be
predictive of extracerebral progression/relapse after chemo-
radiotherapy. In a study reported by Pottgen et al.,15 metabolic
response was measured after chemotherapy followed by
chemo-radiotherapy induction. Metabolic response was
correlated with morphological response (tumor sterilization),
as well as with freedom from extracerebral progression.
Finally, in advanced disease, PET response to the first cycle of
chemotherapy correlated with survival in a prospective
clinical trial.16 The median survival for patients with a
metabolic response was 252 days compared with 151 days for
those without a metabolic response ( p¼ 0.005), with
corresponding 1-year survival rates of 44 and 10%,
respectively. These encouraging findings suggest that PET
could be used in the future to identify patients who could
benefit from switching to an alternative regimen after just one
cycle of chemotherapy. Moreover, PET may ultimately play a
role in phase II trials, both shortening their duration and
limiting drug exposure in non-responding patients.
QUALITY OF LIFE
If survival and response have limited value in clinical
decision-making for individual patients, we must consider
whether QoL may be a more useful endpoint in this regard.
Lung cancer is a highly symptomatic disease, so there is a
great opportunity to demonstrate QoL benefits from
treatment. It is often assumed that a treatment that is less
toxic or more convenient to administer than another will
produce an improvement in QoL. The interplay between
side-effects, symptoms, and clinical benefit is, however,
complex. If a treatment fails to control the disease, it is
unlikely to improve QoL even if less toxic or more
convenient than other options. Therefore, QoL cannot be
considered independent of other outcomes (Figure 1).Copyright © Adis Data Information BV. Una
FIGURE 1. Endpoints and Treatment: Relationships and
Role of Patient-Reported Outcomes.
S54Patients who respond to treatment experience better
symptom relief than those who progress, and those with
higher QoL at baseline have better survival than those with
lower QoL.17,18
QoL is multidimensional, comprising physical, func-
tional, psychological, social, and spiritual domains. Many
validated QoL tools are now available for use in oncology.
Instruments are available that focus on general health, a
specific disease, a specific site of disease, and even specific
treatment options (Figure 2). Three validated tools are
specific to lung cancer: the Lung Cancer Symptom
Scale (LCSS); the EORTC Lung Cancer Module; and the
FACT-L. When incorporating QoL into a clinical trial, it is
imperative to define at the outset the magnitude of change in
QoL that is significant. Experts suggest that a minimal
change of at least 7–10% is necessary for a clinically
significant improvement in QoL.19,20 Other factors that
confound QoL analysis include the lack of a control group in
the trial, which interferes with estimating the magnitude of
benefit, and the inability to separate the effects of palliative
care from those of the therapy, which can lead to an
overestimation of the treatment benefit. In comparative
trials, different completion rates can affect QoL results.
Ideally, all patients would be followed until death or the end
of the trial. Paradoxically, when two treatments do in fact
differ in efficacy, bias caused by attrition can artificially
inflate the change in QoL over time in the inferior treatment
arm because the patients most likely to drop out as a result of
progressive disease or death are those with negative prognos-
tic factors, including significantly worse QoL at baseline.18
Despite these difficulties, several trials in lung cancer
have incorporated QoL measures, and the results demon-
strate how QoL assessments complement survival and
response analyses. TAX326, one of the largest trials to
evaluate QoL prospectively with a validated instrument, was
a randomized phase III trial comparing docetaxel/platinum
combinations with vinorelbine/cisplatin in patients with
stage IIIB/IV NSCLC.21,22 A modest but significant survival
advantage was found with the docetaxel/cisplatin combi-
nation compared with the control arm, although there was no
improvement in survival for the docetaxel/carboplatin armuthorized reproduction of this article is prohibited.
FIGURE 2. Quality of Life Instruments.
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FIGURE 3. TAX 326: Overall Survival. From Fossella
et al.,21 with permission.
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Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Interpreting Clinical Trials in Lung Cancer(Figure 3). The QoL results strengthen the risk : benefit ratio
in favor of docetaxel-based therapy. For example, a modest
improvement in global QoL was seen at each timepoint in
the docetaxel/platinum arms, whereas decrements in the
global QoL score were seen in the control arm (Figure 4). All
patients experienced pain relief with treatment, but the
improvement was significantly greater for the patients
receiving docetaxel/cisplatin than for those receiving
vinorelbine/cisplatin (Figure 5). Taken together, the results
of TAX326 demonstrated that the survival advantage
associated with the docetaxel/cisplatin regimen in advanced
NSCLC does not come at the expense of QoL; the regimen
improves QoL and relieves symptoms for these patients.
QoL is an increasingly important endpoint in early stage
lung cancer trials, particularly as chemotherapy plays a more
prominent role in the management of this disease. For
example, modest survival gains have been reported with
both neoadjuvant and adjuvant approaches; however, these
gains must be considered in the context of the potential for
increased toxicity. QoL was evaluated in the GINEST
project, a pair of randomized phase II trials designed to
evaluate neoadjuvant gemcitabine-based therapy in patients
with clinical stage I/II NSCLC undergoing combined
modality therapy.23 Patients completed the LCSS at baselineCopyright © Adis Data Information BV. Una
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 2007 International Association for the Study of Lung Cancer(before chemotherapy) and again 6 months after surgery.
The majority of patients experienced improved or stable
QoL at 6 months (Table 2). Nearly a quarter experienced a
worsening in QoL at 6 months. These changes appeared to
be related to the presence of pain and fatigue rather than
pulmonary symptoms. Patients at risk of worsening QoL
could not be predicted by the chemotherapy regimen or by
any baseline characteristics, including the baseline QoL
score. That study thus demonstrates that QoL is an important
parameter to evaluate in early stage disease and discuss with
patients when considering combined modality therapy.
Additional research is needed to determine whether patients
likely to experience a decrease in QoL can be identified
before starting therapy.
Clearly, QoL is a useful endpoint for clinical decision-
making, but QoL is rarely evaluated in the clinic. The barrier
is not a lack of valid tools but rather an inability to
incorporate QoL measurements readily into busy daily
practice. The LCSS has recently been computerized for use
on inexpensive hand-held devices such as a pocket personal
computer. Correlation between the paper and electronic
versions is excellent (r¼ 0.93). After the patient completes
the questionnaire on the touch-sensitive screen, a color
graph of the results, including changes over time, is
displayed, providing immediate data for the clinician to
assess (Figure 6). As part of a recent clinical trial, patients
with NSCLC receiving docetaxel/cisplatin, as well as theuthorized reproduction of this article is prohibited.
TABLE 2. Quality of Life Outcomes in the GINEST: Change
from Baseline Lung Cancer Symptom Scale Score 6 Months
after Neoadjuvant Therapy.23
No. of Patients Percentage
Population 42 100
Improved ( 10% change) 4 10
Stable ( 10% change) 28 66
Worsened ( 10% change) 10 24
S55
FIGURE 6. Examples of Pocket Personal Computer Containing the Lung Cancer Symptom Scale and Graphic Report of
Results.
TABLE 3. Attitudes of Patients after Using the Lung
Cancer Symptom Scale Computerized Hand-held Quality
of Life Questionnaire.24
Survey Question
Patients (% CI)
N¼ 103
Easy to use 98 (92–99)
Easy to read 97 (93–100)
Percent taking < 3 min to
complete questionnaire
83 (75–90)
Helped me in speaking to my
doctor or nurse
77 (65–82)
Increased awareness of my QoL and
symptoms of lung cancer
74 (69–85)
Helped me be thorough in discussing
my symptoms of lung cancer
83 (75–90)
Filling out such a tool before seeing
my doctor each week is acceptable
97 (92–99)
QoL, quality of life.
Gralla and Griesinger Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007nurses and physicians caring for them, evaluated the
electronic LCSS administered every 3 weeks.24 Acceptance
of the tool was high by patients and providers alike. Patients
completed the questionnaire in an average of 2.4 min. All
groups reported that communication, satisfaction with the
office visit, and recognition of symptoms were improved
(Table 3 and Table 4). Physicians also felt that the tool
may help them identify patients who are progressing on
therapy earlier or without the use of complicated or intrusive
imaging.
In conclusion, three major endpoints exist for oncology
clinical trials: survival, response, and QoL. When designing
trials, we must ensure that we are asking the right question to
add important new information to a major issue of clinical
concern, and we must have proper statistical design to
answer the study question. In advanced NSCLC, when
survival is measured in months, seemingly small gains in
survival can be clinically significant, but many trials do not
enroll enough patients to detect realistic changes in overall
survival. Meta-analysis is a useful technique for increasing
statistical power and increasing the precision of a treatment
effect when multiple clinical trials have been conducted to
address a similar question. Response remains an important
endpoint for uncontrolled phase II trials, when it is used to
estimate the potential value of an investigational therapy.
QoL is a measurable endpoint that correlates with both
response and survival. Trials are frequently not powered to
detect changes in QoL, and differing survival and response
rates between treatment arms can complicate the interpret-Copyright © Adis Data Information BV. Una
S56ation of QoL results. Nonetheless, QoL must be analysed in
clinical trials in order to assist in interpreting the
risk : benefit ratio for new therapies, particularly in early
stage disease.
In the clinic, response and QoL are the most appropriate
endpoints to evaluate therapy. Because survival is a
dichotomous endpoint, it cannot be used to change the
treatment approach, modify a particular therapy, or
determine whether treatment should be discontinued.uthorized reproduction of this article is prohibited.
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TABLE 4. Attitudes of Physicians and Nurses after Using the Lung Cancer Symptom Scale Computerized Hand-held
Quality of Life Questionnaire.24
Survey Question, % Physicians (N¼ 14) Nurses (N¼ 19) 95% CI
Summary report is easy to interpret 85 95 76–98
Tool lengthened consult time 0 47 24–71
Tool could save time, overall 85 68 57–89
Tool enhanced communication with the patient 84 90 72–97
Tool enhanced satisfaction with patient’s visit 93 84 72–97
Tool increased my awareness of QoL
issues and symptoms of lung cancer
85 95 76–98
Tool could help me identify patients not benefiting
from chemotherapy earlier than usual practice
91 68 62–92
Tool could allow me to order fewer X-rays or CT scans
than usual practice
46 n/a 17–77
Tool could help me identify pain and palliation issues
earlier than usual practice
100 79 69–96
I would use the tool in daily practice 92 84 71–97
I would recommend the tool to colleagues 92 84 71–97
CT, computed tomography; QoL, quality of life.
95% confidence interval for the combined result of physicians’ and nurses’ response.
Journal of Thoracic Oncology * Volume 2, Number 6, Supplement 2, June 2007 Interpreting Clinical Trials in Lung CancerResponse is commonly used, but it is unreliable, expensive,
intrusive, and of minimal value to patients. QoL, although a
patient-reported outcome, can be defined scientifically and
measured with several different validated tools. Recent
advances in electronic technology make capturing QoL data
at each office visit not only possible, but practical, reliable,
and useful for both patients and clinicians.
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